Ostia Sciences Analysis: $2M Raised
What is Ostia Sciences?
Ostia Sciences specializes in identifying and developing beneficial microbes to combat infectious diseases and enhance immune function. Their notable product, Salivaricin 10, is the first phosphorylated antibiotic, showcasing their commitment to microbiome-based healthcare solutions. The company holds extensive patents for their biotherapeutic drugs, positioning them as leaders in disease prevention treatments.
Funding Status
Seed
Product Features & Capabilities
- Salivaricin 10
- Streptococcus salivarius SALI-10
- Pipeline of microbiome therapies
- Health indications for disease prevention
Use Cases
Combat oral and respiratory infections with Salivaricin 10; Regulate immune responses using proprietary probiotics; Develop new antibiotic-like molecules through bacteriocin production; Characterize microbiome states in health and disease; Enhance therapeutic activity against infections
Other Considerations
Secured over $1 million CAD in seed investment; Finalized IP assignment with the University of Toronto; Developed first prototype for microbiome technology
See something that needs updating? Suggest edits to this profile.